Influence of CYP450 Polymorphisms on Analgesic Response to Continuous Ketamine Infusion in Patients with Refractory Migraine: An Exploratory Study
The Journal of Clinical Pharmacology · 2026-11 · 66 (11)
DOI: 10.1002/jcph.70330 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 18.11.2026. Verfasst von Leah Owen‐Oliner und 2 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Continuous intravenous ketamine infusion is an emerging treatment for patients with refractory migraine, but substantial interindividual variability in the timing of analgesic response has been observed. Ketamine is metabolized primarily through CYP2B6 and, to a lesser extent, CYP3A4/5, and genetic variation in these enzymes may contribute to variability in ketamine disposition and downstream metabolite exposure. We hypothesized that CYP metabolic phenotype would be associated with the timing and magnitude of analgesic response and the frequency of ketamine‐associated adverse effects. In this retrospective cohort study, 52 inpatients treated with continuous ketamine infusion for refractory migraine were stratified by CYP2B6 and CYP3A4/5 metabolic phenotype. Longitudinal headache pain was evaluated using linear mixed‐effects models, piecewise cumulative dose‐response models, and time‐to‐response analyses. Ketamine‐associated adverse effects were compared categorically across phenotypes. CYP2B6 rapid metabolizer phenotype was associated with earlier achievement of a ≥50% reduction in headache pain compared with normal metabolizer phenotype (HR 3.21; 95% CI, 1.39–7.45; p = 0.007), but overall cumulative dose‐response trajectories and pain reduction by the end of treatment were similar across CYP2B6 phenotypes. CYP3A4/5 phenotype was not significantly associated with time to response or overall pain reduction; however, the low‐activity subgroup demonstrated a flatter late‐phase cumulative dose‐response trajectory in an exploratory analysis. Adverse‐effect frequency did not differ significantly across phenotypes after multiple‐comparison correction. These findings suggest that CYP2B6 phenotype may influence the timing rather than the magnitude of analgesic response to continuous ketamine infusion. Prospective studies incorporating pharmacokinetic and pharmacodynamic measurements are needed to determine the mechanisms underlying this association.
Zitieren
APA
Owen‐Oliner, L., Denysenko, L., & Schwenk, E. S. (2026). Influence of CYP450 Polymorphisms on Analgesic Response to Continuous Ketamine Infusion in Patients with Refractory Migraine: An Exploratory Study. The Journal of Clinical Pharmacology, 66(11). https://doi.org/10.1002/jcph.70330
Vancouver
Owen‐Oliner L, Denysenko L, Schwenk ES. Influence of CYP450 Polymorphisms on Analgesic Response to Continuous Ketamine Infusion in Patients with Refractory Migraine: An Exploratory Study. The Journal of Clinical Pharmacology. 2026;66(11). doi:10.1002/jcph.70330
BibTeX
@article{OwenOliner2026,
author = {Owen‐Oliner, Leah and Denysenko, Lex and Schwenk, Eric S.},
title = {Influence of CYP450 Polymorphisms on Analgesic Response to Continuous Ketamine Infusion in Patients with Refractory Migraine: An Exploratory Study},
journal = {The Journal of Clinical Pharmacology},
year = {2026},
volume = {66},
number = {11},
doi = {10.1002/jcph.70330}
}
EUVIMED